(Total Views: 415)
Posted On: 08/26/2024 11:01:56 AM
Post# of 148870
How about a drug conjugate of LL with a VEGF inhibitor such as Bevacizumab?
This from the Copilot AI:
"Conjugating a monoclonal antibody (MAb) CCR5 blocker with a VEGF inhibitor could offer several theoretical benefits, particularly in cancer therapy:
Enhanced Targeting and Efficacy
Dual Targeting: By combining a CCR5 blocker with a VEGF inhibitor, the conjugate can simultaneously target two critical pathways involved in tumor growth and metastasis. CCR5 is involved in tumor cell migration and metastasis, while VEGF promotes angiogenesis (the formation of new blood vessels) that supply the tumor with nutrients12.
Improved Delivery: The MAb can specifically target cancer cells expressing CCR5, delivering the VEGF inhibitor directly to the tumor site. This targeted delivery can enhance the efficacy of the VEGF inhibitor by concentrating its action where it is most needed1.
Reduced Side Effects
Minimized Off-Target Effects: Targeted delivery reduces the exposure of healthy tissues to the VEGF inhibitor, potentially minimizing side effects such as hypertension and impaired wound healing, which are common with systemic VEGF inhibition3.
Synergistic Effects
Synergistic Anti-Tumor Activity: Blocking CCR5 can reduce tumor cell migration and metastasis, while inhibiting VEGF can starve the tumor of its blood supply. Together, these actions can have a synergistic effect, leading to more effective tumor suppression12.
Plus, such a conjugate would be patentable, would it not?
This from the Copilot AI:
"Conjugating a monoclonal antibody (MAb) CCR5 blocker with a VEGF inhibitor could offer several theoretical benefits, particularly in cancer therapy:
Enhanced Targeting and Efficacy
Dual Targeting: By combining a CCR5 blocker with a VEGF inhibitor, the conjugate can simultaneously target two critical pathways involved in tumor growth and metastasis. CCR5 is involved in tumor cell migration and metastasis, while VEGF promotes angiogenesis (the formation of new blood vessels) that supply the tumor with nutrients12.
Improved Delivery: The MAb can specifically target cancer cells expressing CCR5, delivering the VEGF inhibitor directly to the tumor site. This targeted delivery can enhance the efficacy of the VEGF inhibitor by concentrating its action where it is most needed1.
Reduced Side Effects
Minimized Off-Target Effects: Targeted delivery reduces the exposure of healthy tissues to the VEGF inhibitor, potentially minimizing side effects such as hypertension and impaired wound healing, which are common with systemic VEGF inhibition3.
Synergistic Effects
Synergistic Anti-Tumor Activity: Blocking CCR5 can reduce tumor cell migration and metastasis, while inhibiting VEGF can starve the tumor of its blood supply. Together, these actions can have a synergistic effect, leading to more effective tumor suppression12.
Plus, such a conjugate would be patentable, would it not?
(4)
(0)Scroll down for more posts ▼
